Call for Abstract
2nd International Conference on Prostate Cancer and Therapeutics, will be organized around the theme “Encompassing the Possibilities and Novel Targets in Prostate Cancer Research”
Prostate Cancer 2016 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Prostate Cancer 2016
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Prostate cancer is an abnormal and uncontrolled growth of cells found in your prostate gland. Causes of prostate cancer include age, genetics, diet, medication, obesity and sexually transmitted diseases. Almost all prostate cancers are adenocarcinomas. Interventional oncology procedures provide minimally invasive, targeted treatment of prostate cancer. Prostate cancer often has no early symptoms. Advanced prostate cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions. Molecular Oncology of Prostate Cancer emphasizes the genes, proteins and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed prostate cancer. Cellular Oncology involves in basic and translational cancer research on the cell and tissue level of prostate. Prostate cancer usually grows very slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve health or help you live longer.
- Track 1-1Metastatic prostate cancer
- Track 1-2Prostate cancer screening
- Track 1-3Prostate cancer awareness
- Track 1-4Causes of prostate cancer
- Track 1-5Classification of prostate cancer
- Track 1-6Symptoms of prostate cancer
- Track 1-7Prostate cancer and genetics
- Track 1-8Prostate cancer and obesity
- Track 1-9Prostate cancer and vascular diseases
Prostate cancer can cause a number of complications from local and distant spread which include blockage of the bladder by urethral obstruction, bleeding in the urine, blockage of the tubes draining the kidneys into the bladder (ureters), pelvic pain, bony pain, tiredness and death. Prostate cancer most commonly spreads to lymph nodes in other parts of the body is known as Lymph node cancer. Long-term complications which can arise following surgery include Impotence, Incontinence, Obstruction and disease recurrence. Cancers of the prostate can spread to esophagus which is known as Esophageal cancer. However, the lack of testosterone can lead to a number of side effects which include Osteoporosis, Diabetes, Cardiovascular disease and Weight gain.A recent large study showed an increased risk of pancreas cancer in people with a father, brother or son diagnosed with prostate cancer.
- Track 2-1Benign Prostatic Hyperplasia
- Track 2-2Psychological complications of prostate Cancer
- Track 2-3Testosterone and prostate enlargement
- Track 2-4Longer term incontinence of prostate cancer
- Track 2-5Urinary problems of prostate cancer
- Track 2-6Prostate cancer and bowel problems
- Track 2-7Prostate cancer and bladder problems
- Track 2-8Prostatic adenocarcinoma
- Track 2-9Benign Prostatic Hypertrophy
- Track 2-10Prostate cancer reoccurrence
Prostatitis is a frequently painful condition that involves inflammation of the prostate and sometimes the areas around the prostate. Types of Prostatitis include Acute bacterial prostatitis (ABP), Chronic bacterial prostatitis (CBP), Nonbacterial prostatitis and Prostatodynia .Causes and Symptoms of Prostatitis include: urinary tract infection, recent bladder infection, enlarged prostate and symptoms-frequent urge to urinate, difficulty urinating, pain or burning during urination, chills and fever. The treatment for prostatitis depends on the underlying cause and type of prostatitis. Treatment modalities may include the following: Antibiotics, Anti-inflammatory medications, Alpha-blockers, Lifestyle changes and Acupuncture. Prevention of prostatitis includes practice good hygiene and keep your penis clean, drink enough fluids to cause regular urination and early treatment of a possible urinary tract infection.
- Track 3-1Acute bacterial prostatitis
- Track 3-2Chronic bacterial prostatitis
- Track 3-3Chronic pelvic pain in men
- Track 3-4Granulomatous prostatitis
- Track 3-5Nonbacterial prostatitis
- Track 3-6Prostatitis causes and symptoms
- Track 3-7Treatment of prostatitis
- Track 3-8Prevention of prostatitis
Prostatic calcification is a common finding, especially after the age of 50. They may be solitary but usually occur in clusters. Interventional oncology procedures provide minimally invasive, targeted treatment of prostate cancer. Variable appearance from fine granules to irregular lumps and can range in size from 1 to 40mm. If there is significant prostatic hypertrophy the calcifications can project well above the pubic symphysis. Prostatic calcification is most often an incidental, asymptomatic finding but it can cause symptoms such as dysuria, infection, haemautira, obstruction or Chronic Pelvic Pain.
- Track 4-1Epidemiology for prostate cancer
- Track 4-2Pathology for prostate cancer
- Track 4-3Radiographic features for prostate cancer
- Track 4-4Treatment and prognosis for prostate cancer
Prostate Staging is a way of describing where the cancer is located, if or where it has spread, and whether it is affecting other parts of the body. Doctors use diagnostic methods to find out the cancer's stage, so staging may not be complete until all of the tests are finished. Staging for prostate cancer also involves looking at test results to find out if the cancer has spread from the prostate to other parts of the body. Knowing the stage helps the doctor to decide what kind of treatment is best and can help predict a patient's prognosis, which is the chance of recovery. There are different stage descriptions for different types of cancer.
- Track 5-1Early stage prostate cancer
- Track 5-2Prostate cancer stages
- Track 5-3Metastatic prostate cancer
- Track 5-4PSA test
- Track 5-5Prostate cancer and gleason score
Tests commonly used to screen for prostate cancer include PSA screening - Prostate specific antigen (PSA) test measures the level of PSA in the blood. PSA is a substance made by the prostate. The levels of PSA in the blood can be higher in men who have prostate cancer. The main type of surgery for prostate cancer is known as a radical prostatectomy. In this operation, the surgeon removes the entire prostate gland plus some of the tissue around it, including the seminal vesicles. The Prostascint scan was developed in order to help doctors detect the spread of prostate cancer to other parts of the body, particularly the lymph node cancer. Clinical case discussions on prostate cancer include Case Reports on Prostate Cancer, Case Study: Castrate-Resistant Prostate Cancer. Proton therapy for prostate cancer is a treatment option that involves using a focused ray of proton particles to destroy cancerous tissues. The disease diagnosis and screening segment is expected to total $12.1 billion in 2012 and $17.4 billion in2017, a CAGR of 7.5%.
- Track 6-1PSA test
- Track 6-2Possible benefits of the PSA test
- Track 6-3Risks of the PSA test
- Track 6-4After a PSA test
- Track 6-5PSA testing for men at higher risk of prostate cancer
Radical prostatectomy is an operation to remove the prostate gland and some of the tissue around it. It is done to remove prostate cancer. This operation may be done by open surgery or it may be done by laparoscopic surgery. In open surgery, the surgeon makes an incision to reach the prostate gland. Cancer Sciences is a study of cancer cells that causes tumor and technically the therapy is processed. Curative treatment options include Cancer therapies such as radical prostatectomy (RP), external beam radiotherapy and brachytherapy.Active surveillance is a strategy of close monitoring, typically using serum PSA, repeat prostate biopsies and/or MRI, keeping curative treatment in reserve for those with early evidence of disease progression. Anti-cancer drugs are also called anti-neoplastic agents or chemotherapeutic agents which are used to treat prostate cancer.
- Track 7-1Prostatectomy
- Track 7-2Robotic surgery for prostate cancer
- Track 7-3Transurethral resection of the prostate
- Track 7-4Prostate cancer recovery
- Track 7-5Surgical risks of prostate cancer
- Track 7-6Prostate Cancer presurgical support
- Track 7-7Prostate Cancer postsurgical support
A radical prostatectomy is an operation to remove the prostate gland and some of the tissue around it. It is done to remove prostate cancer. This operation may be done by open surgery or it may be done by laparoscopic medicine and surgery. In open surgery, the surgeon makes an incision to reach the prostate gland. Depending on the case, the incision is made either in the lower belly or in the perineum between the anus and the scrotum. For laparoscopic surgery, the surgeon makes several small incisions in the belly. Robotic-assisted laparoscopic radical prostatectomy is surgery done through small incisions in the belly with robotic arms that translate the surgeon's hand motions into finer and more precise action. Risks after surgery are Problems controlling bowel movements, Problems controlling urine, Erectile Dysfunction, Injury to the rectum, Urethral stricture. As a segment, surgical and radiation therapy should total $9 billion in 2012 and nearly $14.3 billion in 2017, a CAGR of 9.7%.A prosthesis is a device designed to replace a missing part of the body or to make a part of the body work better. Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate.
- Track 8-1Open surgery for prostate cancer
- Track 8-2Laparoscopic surgery for prostate cancer
- Track 8-3Robotic-assisted laparoscopic radical prostatectomy
- Track 8-4Risks after surgery for prostate cancer
Early prostate cancers usually don’t cause symptoms, but more advanced cancers are sometimes first found because of symptoms they cause. Whether cancer is suspected based on cancer screening tests or symptoms, the actual diagnosis can only be made with a prostate biopsy. TRUS is often used to look at the prostate when a man has a high PSA level or has an abnormal DRE result. It is also used during a prostate biopsy to guide the needles into the right area of the prostate. Pathologists grade prostate cancers according to the Gleason system. This system assigns a Gleason grade, using numbers from 1 to 5 based on how many cells in the cancerous tissue look like normal prostate tissue.
- Track 9-1Medical history and physical exam for prostate cancer
- Track 9-2Transrectal ultrasound for prostate cancer
- Track 9-3Grading prostate cancer
- Track 9-4Imaging tests to look for prostate cancer spread
- Track 9-5Lymph node biopsy for prostate cancer
There are many treatment options for prostate cancer that is confined to the prostate gland. Historical standard options include Radical prostatectomy, External beam therapy and Active surveillance. Cancer that leads to bone metastasis and survival for bone cancers has improved in recent years by Bone marrow Cancer Survival.The newer options avoid or minimize some of the unpleasant side effects sometimes associated with the standard therapies. Bone cancer stages are important for the treatment of cancer. These options include nerve-sparing radical prostatectomy, conformal external beam radiation therapy, image-guided radiation therapy, proton beam therapy and brachytherapy. Sarccoma cancer of prostate occurs in relatively younger men between the ages of 35 and 60.A digital rectal examination will be done to assess the prostate gland. A blood test will be performed to measure your PSA level and to assess your response to the treatment. An elevated level of PSA can indicate the presence of prostate cancer.
- Track 10-1Active surveillance for prostate cancer
- Track 10-2Proton therapy for prostate cancer
- Track 10-3Radiation therapy for prostate cancer
- Track 10-4Hormone therapy for prostate cancer
- Track 10-5Chemotherapy for prostate cancer
- Track 10-6Immunotherapy for prostate cancer
Treatments that slow the spread of advanced prostate cancer and relieve symptoms often cause side effects. Some patients, often those who are older, decide that the risk of side effects outweighs the benefits of treatment. These patients may choose not to treat their advanced prostate cancer. Endocrine therapy may reduce tumor size and levels of prostate specific antigen (PSA) in most men. Provenge is an immune therapy created by harvesting immune cells from a patient, genetically engineering them to fight prostate cancer, and then infusing them back into the patient.
- Track 11-1Endocrine therapy and prostate cancer
- Track 11-2Endocrine drugs for prostate cancer
- Track 11-3Provenge for advanced prostate cancer
- Track 11-4Antiandrogens for prostate cancer
Prostate cancer patients undergoing conventional therapies also can benefit from nutritional and herbal support. Nutrition plays a very important role in cancer treatment. Prostate Oncology analytics provides evidence-based care, utilizes a counseling model within traditional preauthorization management for chemotherapeutic drugs, symptom-management drugs and supporting agents. Scientific evidence shows that nutrition and physical activity are the two most important modifiable risk factors to alter the course of cancer, prevent its occurrence, and stop its progression. Prostate oncologic emergency may be defined as any acute potentially morbid or life-threatening event directly or indirectly related to a patient's tumor or its treatment. Supplements are intended to provide nutritional support. Herbal medicines rarely have significant side effects when used appropriately and at suggested doses. Some types of cancers rarely spread to the brain, such as colon cancer or prostate cancer. Brain tumor treatment can be done by Radiation, Surgery and Chemotherapy which depends on the size and type of the tumor. Measures may be taken, starting 2 weeks before surgery, to prevent surgical complications, reduce pain and swelling, speed healing, support the immune system, and reduce or prevent the spread of cancer cells. Measures may be taken, continuing for 4 weeks after surgery, to prevent surgical complications, reduce pain and swelling, speed healing, support the immune system, and reduce or prevent the spread of cancer cells.
- Track 12-1Naturopathic medicine and prostate Cancer
- Track 12-2Nutrition and prostate Cancer
- Track 12-3Herbal medicine and prostate Cancer
- Track 12-4Traditional chinese medicine for prostate cancer
- Track 12-5Hypnotherapy and prostate cancer
Scientists continue to look at new ways to prevent, treat, and diagnose prostate cancer. Although the specific underlying mechanisms of prostate carcinogenesis remain unknown, prostate cancer is thought to result from a combination of genetic and environmental factors altering key cellular processes. Research has already led to a number of advances in these areas. Some researchers think that diet may affect a man's chances of developing prostate cancer. Active mitochondrial mutagenesis in prostate cancer suggests a prominent role of increased cellular oxidative stress in neoplastic transformation and the increased susceptibility of neoplastic cells to oxidative damage. Some research suggests that high levels of testosterone may increase a man's risk of prostate cancer. As in the normal prostate, the initial stages of prostate cancer progression depend on androgens that increase proliferation and inhibit apoptosis. Researchers are studying changes in genes that may increase the risk for developing prostate cancer. Several studies have explored ways to prevent prostate cancer. Scientists are also looking at ways to stop prostate cancer from returning in men who have already been treated for the disease. Some researchers are working to develop new blood tests to detect the antibodies that the immune system produces to fight prostate cancer.
- Track 13-1Prevention research prostate cancer
- Track 13-2Prostate cancer research on new blood tests
- Track 13-3Personalized medicine for prostate cancer
- Track 13-4Castration-resistant prostate cancer research
- Track 13-5Prostate cancer dietary research
- Track 13-6Genetic research on prostate cancer
New technology is offering hope that men could one day avoid having to undergo an invasive procedure to determine whether they might have prostate cancer. Pomegranate fruit extracts possess polyphenol and other compounds with ant proliferative and anti-inflammatory effects in prostate. Feeding of pomegranate fruit extract to mice affords substantial protection from the adverse effects of UVB radiation via modulation in early biomarkers of photo carcinogenesis. Biological molecules that provide a clear indication of disease also known as biomarkers are used for molecular tests to diagnose prostate cancer. If patients with multiple lymphomatous polyposis of the gastro intestinal tract have obstructive urinary symptoms, involvement of the prostate gland by lymphoma should be considered, and appropriate diagnostic studies should be performed. The majority of prostate cancer deaths result from metastatic disease, which tends to initially respond to well to chemotherapeutic agents that cause DNA damage. New biomarkers are allowing more precisely detecting prostate cancer, guiding decisions about the therapies we use to treat, monitoring response to treatment and track the progression of cancer.
- Track 14-1Cryotherapy for prostate cancer
- Track 14-2High-intensity focused ultrasound for prostate cancer
- Track 14-3Focal therapies for prostate cancer
- Track 14-4Molecular imaging and prostate cancer
- Track 14-5Urinary biomarkers and prostate cancer
- Track 14-6Epigenetic biomarkers and prostate cancer
Growth in the overall urological device market will be driven by improved diagnosis rates, particularly for prostate cancer and benign prostatic hyperplasia. Comparative oncology is the study of prostate cancer that naturally occurs in animals and the comparison to its human counterpart in order to identify treatments and cures that can benefit both humans and animals. Radio Oncology or radiotherapy is therapy using ionizing radiation, generally as part of prostate cancer treatment to control or kill malignant cells. External beam radiation therapy is currently the most frequently used primary treatment method for prostate cancer, but it is predicted to be overtaken by robotic prostatectomy surgery by 2013. Other treatments include brachytherapy, cryotherapy and high-intensity focused ultrasound (HIFU), with the developing market for HIFU estimated to grow at a compound annual growth rate (CAGR) of 91% by 2016.Clinical Oncology encompasses the nonsurgical aspects of cancer care, including therapeutic administration of ionizing radiation and cytotoxic chemotherapy.
- Track 15-1Recent advances in prostate cancer drugs
- Track 15-2Prostate cancer devices
- Track 15-3Castration resistant prostate cancer therapeutics
- Track 15-4Androgen deprivation therapy
- Track 15-5Prostate cancer vaccines
Clinical scientists and laboratory investigators study the basic biology of prostate cancer to hunt for even better ways to detect it and treat it. Preclinical trials for metastatic prostate cancer and Clinical trials for advanced prostate cancer play a crucial role in moving new treatments to patients. New treatments on prostate cancer include Surgery, Radiation, Hormonal Therapy, Chemo therapy, Biologic therapy and Bisphosphonate therapy. Unlike vaccines against infections like measles or mumps, prostate cancer vaccines are designed to help treat, not prevent, prostate cancer. One possible advantage of these types of treatments is that they seem to have very limited side effects. Drug therapeutics is expected to reach $8.1 billion in 2012 and nearly $18.6 billion in 2017, a CAGR of 18%.
- Track 16-1Clinical trials for metastatic prostate cancer
- Track 16-2Clinical trials for advanced prostate cancer
- Track 16-3New treatments on prostate cancer
- Track 16-4Vaccines in clinical trials for prostate cancer
Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from challenges and chances in prostate cancer research .A urologist, a radiation oncologist, and a medical oncologist will give you the most comprehensive assessment of the available treatments and expected outcomes. Nuclear scans make pictures based on the body’s chemistry rather than on physical shapes and forms PET/CT scanners give information on any areas of increased cell activity. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. Taken together, the prostate biopsy scenario is currently becoming distinctively complex. It has clearly moved far beyond any prostate cancer detection, or avoiding biopsy-related complications such as infections or patients’ anxiety. Importantly, the future of prostate imaging especially of multiparametric MRI-based technology has already begun.
- Track 17-1Medical oncology for prostate cancer
- Track 17-2Nuclear and CT imaging for prostate cancer
- Track 17-3Urology and prostate cancer
- Track 17-4The future of prostate imaging
An oncologist is a doctor who specializes in treating people with cancer. The oncologist’s research into the causes, prevention, detection, and treatment of prostate is going on in many medical centers throughout the world. Understanding the mechanisms of prostate cancer initiation and progression should have a significant impact on development of novel therapeutic approaches that can help to combat the disease. New research on gene changes linked to prostate cancer is helping scientists better understand how prostate cancer develops. Ductal adenocarcinoma often involves the central ducts of the gland and may present as an exophytic papillary lesion in the prostatic urethra. The tumour presents in elderly men with haematuria or obstructive symptoms. For this reason, they are often seen in Transurethral Resection (TUR) specimens and at Radical Prostatectomy (RP), and are less often found in needle biopsies. Researchers continue to look for foods (or substances in them) that can help lower prostate cancer risk. The diabetes drugs will reduce glucose uptake, disrupt glycolysis, and reduce tumor growth without significant side effects in both adenocarcinoma pancreas and prostate. Doctors agree that the prostate-specific antigen (PSA) blood test is not a perfect test for finding prostate cancer early. It misses some cancers, and in other cases it is elevated when cancer isn’t present. Researchers are working on two strategies to address this problem. Newer treatments are being developed, and improvements are being made among many standard prostate cancer treatment methods. Several other types of vaccines to treat prostate cancer are being tested in clinical trials. One example is PROSTVAC, which uses a virus that has been genetically modified to contain prostate-specific antigen (PSA).
- Track 18-1Prostate cancer experts and specialists
- Track 18-2Oncologist: Prostate cancer specialist insights
- Track 18-3Prostate surgeon insights
- Track 18-4Prostrate oncology specialists careers
- Track 18-5Prostate Cancer pathologists
Prostate cancer case reports play a crucial role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Oncology Esthetics is the practice of safe and beneficial spa services by individuals trained to understand how prostate cancer and associated medical treatments affect the body. Prostate Oncology Nutrition includes the current therapies used to treat pediatric cancer and nutrition related side effects. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients. If a patient with prostate carcinoma develops metastatic disease of musculoskeletal oncolgy, the bone lesion may become dense and hard. There are currently more than several Phase III drug trials and more than 90 Phase I/II trials in process for prostate cancer in North America and Europe.
- Track 19-1Case reports on screening
- Track 19-2Case reports on diagnosis
- Track 19-3Case reports on treatment
- Track 19-4Case reports on prevention
A key ingredient in successful entrepreneurship is self-knowledge. Prostate Cancer-2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from prostate cancer to signaling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts .The speakers will discuss state-of-the-art treatments, current guidelines, clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice. This session will include combined efforts of World-renowned speakers, the most recent techniques, developments, and the newest updates in prostate cancer.